December 30, 2016 / 1:52 PM / 9 months ago

Growth hormone deficiency drug from OPKO and Pfizer fails study

Dec 30 (Reuters) - OPKO Health Inc said on Friday its experimental drug for growth hormone deficiency did not provide a statistically significant benefit over a placebo in a late-stage study.

The drug, hGH-CTP, is being developed in collaboration with Pfizer Inc.

Growth hormone deficiency is a rare disorder characterized by the inadequate secretion of the growth hormone.

Reporting by Divya Grover in Bengaluru

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below